Vimarsana
Biggest News Aggregation in the World

Caxton Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Caxton Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Caxton Corp Today - Breaking & Trending Today

Caxton Corp Has $2.61 Million Position in Rezolute, Inc. (NASDAQ:RZLT) - Vimarsana News

Caxton Corp Has $2.61 Million Position in Rezolute, Inc. (NASDAQ:RZLT)

Caxton Corp reduced its holdings in Rezolute, Inc. (NASDAQ:RZLT – Free Report) by 6.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,318,967 shares of the company’s stock after selling 84,190 shares during the quarter. Rezolute accounts for 7.5% of Caxton Corp’s […]

Caxton Corp Sells 46,599 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Vimarsana News

Caxton Corp Sells 46,599 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV)

Caxton Corp decreased its holdings in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) by 68.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,725 shares of the company’s stock after selling 46,599 shares during the period. Elevation Oncology makes up approximately 0.1% of […]

VectivBio Holding AG (NASDAQ:VECT) Sees Large Growth in Short Interest - Vimarsana News

VectivBio Holding AG (NASDAQ:VECT) Sees Large Growth in Short Interest

VectivBio Holding AG (NASDAQ:VECT – Get Rating) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 105,400 shares, an increase of 85.9% from the February 28th total of 56,700 shares. Based on an average daily volume of 20,500 shares, the short-interest ratio is […]

Cardiff Oncology (NASDAQ:CRDF) PT Lowered to $7.00 - Vimarsana News

Cardiff Oncology (NASDAQ:CRDF) PT Lowered to $7.00

Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its price objective dropped by investment analysts at Piper Sandler from $20.00 to $7.00 in a report released on Friday, The Fly reports. Piper Sandler’s price objective points to a potential upside of 442.64% from the stock’s previous close. A number of other brokerages have also recently issued […]

$3.09 Million in Sales Expected for Kala Pharmaceuticals, Inc. (NASDAQ:KALA) This Quarter - Vimarsana News

$3.09 Million in Sales Expected for Kala Pharmaceuticals, Inc. (NASDAQ:KALA) This Quarter

Wall Street brokerages predict that Kala Pharmaceuticals, Inc. (NASDAQ:KALA – Get Rating) will announce sales of $3.09 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from $2.04 million to $5.00 million. Kala Pharmaceuticals reported sales of $3.27 million during the same […]